3-methylidenyl-2-indolinone modulators of protein kinase

Details 3-methylidenyl-2-indolinone modulators of protein kinase 3-methylidenyl-2-indolinone modulators of protein kinase

2005-02-15

2005-02-15

Lambkin, Deborah C. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S343000, C514S235500, C548S486000, C546S278400, C544S144000

Reexamination Certificate

active

06855730

ABSTRACT:
The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

REFERENCES:
patent: 2872372 (1959-02-01), Hull
patent: 2968557 (1961-01-01), Burgardt et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4642309 (1987-02-01), Michel et al.
patent: 4826847 (1989-05-01), Michel et al.
patent: 4853403 (1989-08-01), Shiraishi et al.
patent: 4868304 (1989-09-01), Larok et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5051417 (1991-09-01), Nadler et al.
patent: 5057538 (1991-10-01), Shiraishi et al.
patent: 5089516 (1992-02-01), Shiraishi et al.
patent: 5124347 (1992-06-01), Connor et al.
patent: 5202341 (1993-04-01), Shiraishi et al.
patent: 5206261 (1993-04-01), Kawaguchi et al.
patent: 5217999 (1993-06-01), Levitzki
patent: 5302606 (1994-04-01), Spada et al.
patent: 5322950 (1994-06-01), Sircar et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5339992 (1994-08-01), Barthomeuf et al.
patent: 5374652 (1994-12-01), Buzzetti et al.
patent: 5382593 (1995-01-01), Le Baut et al.
patent: 5409949 (1995-04-01), Buzzetti et al.
patent: 5650415 (1997-07-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5849710 (1998-12-01), Battistini et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 286870 (1964-12-01), None
patent: 2012634 (1991-09-01), None
patent: 878539 (1953-05-01), None
patent: 2159360 (1973-06-01), None
patent: 2159361 (1973-06-01), None
patent: 2159362 (1973-06-01), None
patent: 2159363 (1973-06-01), None
patent: 2321656 (1973-11-01), None
patent: 3310891 (1984-09-01), None
patent: 3426419 (1986-01-01), None
patent: 0 351 213 (1990-01-01), None
patent: 0 566 226 (1993-01-01), None
patent: 0 525 472 (1993-02-01), None
patent: 0 580 502 (1994-01-01), None
patent: 0 632 102 (1994-06-01), None
patent: 0 626 377 (1994-11-01), None
patent: 0 662 473 (1995-07-01), None
patent: 0 788 890 (1997-08-01), None
patent: 1398224 (1965-03-01), None
patent: 2689397 (1993-10-01), None
patent: 809691 (1959-04-01), None
patent: 835473 (1960-05-01), None
patent: 1384599 (1975-02-01), None
patent: 62-29570 (1987-02-01), None
patent: 62-39564 (1987-02-01), None
patent: 63-141955 (1988-06-01), None
patent: 5-58894 (1993-03-01), None
patent: 9-286777 (1997-11-01), None
patent: 8807035 (1988-09-01), None
patent: 9115495 (1991-10-01), None
patent: 9221660 (1992-04-01), None
patent: 9207830 (1992-05-01), None
patent: 9113055 (1992-09-01), None
patent: 9220642 (1992-11-01), None
patent: 9301182 (1993-01-01), None
patent: 9403427 (1994-02-01), None
patent: 9410202 (1994-05-01), None
patent: 9414808 (1994-07-01), None
patent: 9501349 (1995-01-01), None
patent: 9514667 (1995-06-01), None
patent: 9517181 (1995-06-01), None
patent: 9600226 (1996-01-01), None
patent: 9616964 (1996-06-01), None
patent: 9622976 (1996-08-01), None
patent: 9632380 (1996-10-01), None
patent: 9725986 (1997-07-01), None
patent: 9736867 (1997-10-01), None
patent: 9807695 (1998-02-01), None
patent: 9910325 (1999-04-01), None
STN International ® CAPLUS Database, Accession No. 1990:478106; Andreani et al. European Jounal of Medicinal Chemistry 25(2), 187-90 (1990), abstract.*
Treibs et al., “Über isoindigoide Farbstoffe der Pyrrol-Reihe,” Liebigs Ann. Chem. 702:112-130 (1967).
Abramovitch and Hey, “Internuclear cyclisation. Part VII. Naphth[3:2:1-cd]oxindoles,”J. Chem. Soc.pp. 1697-1703 (1954).
Abramovitch et al., “A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement,”Chemistry and Industry44:1871 (1967).
Abramovitch, Bellstein Reg. No. 236050,J. Chem. Soc.,pp. 1697, 1700 (1954).
Akbasak and Suner-Akbasak et al., “Oncogenes: cause or consequences in the development of glial tumors,”J. Neurol. Sci.111:119-133 (1992).
Andreani et al., “In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,”Arzn imittel-Forschung Drug Res arch48 (II): 727-729(1998).
Andreani et al., “Potential antitumor agents. 25[1]. Synthesis and cytotoxic activity of 3-(2-chloro-3-indolylmethlene) 1,3-Dyhydroindol-2-ones,”AntiCancer Research16:3585-3588 (1996).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones,”Eur. J. Med. Chem.25:187-190 (1990).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones,”Chemical Abstracts,vol. 113, abstract No. 78106 (1990).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,”Eur. J. Med. Chem.28:653-657 (1993).
Andreani et al., “Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones,”Eur. J. Med. Chem.27:167-170 (1992).
Andreani et al., “Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo [2, 1-b]thiazolymethylene)-2-indolinones,” Eur. J. Med. Chem. 32:919-924 (1997).
Andreani et al., “Synthesis of lactams with potential cardiotonic activity,”Eur. J. Med. Chem.28:825-829 (1993).
Arteaga et al., “Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice,”J. Clin. Invest,84:1418-1423 (1989).
Autrey and Tahk, “The Synthesis and Sterochemistry of Some isatylideneacetic Acid Derivatives,”Tetrahedron23:901-917 (1967).
Bahner et al., “Benzylideneindenes with Oxygen Attached to the Indene Ring,”J. Med. Chem.12:721-722 (1969).
Bamfield et al., “Diels-Alder Reactions of Oxindolylideneacetone,”J. Chem. Soc.(C) pp. 1028-1030 (1966).
Baserga, “Oncogenes and the strategy of growth factors,”Cell79:927-930 (1994).
Baserga, “The insulin-like growth factor I receptor: a key to tumor growth?”Cancer Res.55:249-252 (1995).
Beilstein Reg. No. 252929 (1998).
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”FASEB J.6:3403-3409 (1992).
Buzzetti et al., “Cinnamamid Analogs as Inhibitors of Protein Tyrosin Kinases,” IIFarmaco48 (5):615-636 (1993).
Carpened et al., “Identification and Measurement of Oxindole (2-indolinon ) in th Mammalian Brain and Oth r Rat Organs,”Analytical Biochemistry244:74-79 (1997).
Chao, “Growth Factor Signaling: Where is the Specificity?”Cell68:995-997 (1992).
Chen et al., “Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron,”Chinese Journal of Physiology40(3):149-156 (1997).
Coda et al., “3-(4-methylbenzilidene)-1-,3-dihydroindol-2-one,” Journal of the Chemical Society, Perkin Transactions 2 4: 615-620 (1984).
Coppola et al., A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth FactorMolecular and Cellular Biology14:4588-4595 (1994).
Damiani et al., “Inhibition of Cooper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals,”Biochemical Pharmacology48(6): 1155-1161 (1994).
Davis et al., “Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds,”Journal of Medicinal Chemistry16(9):1043-1045 (1973).
De Vries et al., “The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science255:989-991 (1992).
Dickson et al., “Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer,”Cancer Treatment Res.61:249-273 (1992).
Elliot, “1-methyl-2-(3-oxindolidenmethyl)-pyridinium,” Database Crossfire, Beilstein Ref. No.

Affiliated with

Also associated with

Rating

3-methylidenyl-2-indolinone modulators of protein kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-methylidenyl-2-indolinone modulators of protein kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-methylidenyl-2-indolinone modulators of protein kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3458280